158 related articles for article (PubMed ID: 22904270)
1. Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease.
Makino H; Aoki M; Hashiya N; Yamasaki K; Azuma J; Sawa Y; Kaneda Y; Ogihara T; Morishita R
Arterioscler Thromb Vasc Biol; 2012 Oct; 32(10):2503-9. PubMed ID: 22904270
[TBL] [Abstract][Full Text] [Related]
2. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease.
Morishita R; Aoki M; Hashiya N; Makino H; Yamasaki K; Azuma J; Sawa Y; Matsuda H; Kaneda Y; Ogihara T
Hypertension; 2004 Aug; 44(2):203-9. PubMed ID: 15238569
[TBL] [Abstract][Full Text] [Related]
3. Combined Analysis of Clinical Data on HGF Gene Therapy to Treat Critical Limb Ischemia in Japan.
Morishita R; Shimamura M; Takeya Y; Nakagami H; Chujo M; Ishihama T; Yamada E; Rakugi H
Curr Gene Ther; 2020; 20(1):25-35. PubMed ID: 32416690
[TBL] [Abstract][Full Text] [Related]
4. Clinical Safety and Preliminary Efficacy of Plasmid pUDK-HGF Expressing Human Hepatocyte Growth Factor (HGF) in Patients with Critical Limb Ischemia.
Cui S; Guo L; Li X; Gu Y; Fu J; Dong L; Song H; Chen X; Lu Y; Hu C; Xiao F; Zhu D; Wu Z; Zhang Q
Eur J Vasc Endovasc Surg; 2015 Oct; 50(4):494-501. PubMed ID: 26122834
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor as potential cardiovascular therapy.
Nakagami H; Kaneda Y; Ogihara T; Morishita R
Expert Rev Cardiovasc Ther; 2005 May; 3(3):513-9. PubMed ID: 15889978
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial.
Powell RJ; Goodney P; Mendelsohn FO; Moen EK; Annex BH;
J Vasc Surg; 2010 Dec; 52(6):1525-30. PubMed ID: 21146749
[TBL] [Abstract][Full Text] [Related]
7. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia.
Baumgartner I; Pieczek A; Manor O; Blair R; Kearney M; Walsh K; Isner JM
Circulation; 1998 Mar; 97(12):1114-23. PubMed ID: 9537336
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor.
Kessler JA; Shaibani A; Sang CN; Christiansen M; Kudrow D; Vinik A; Shin N;
Clin Transl Sci; 2021 May; 14(3):1176-1184. PubMed ID: 33465273
[TBL] [Abstract][Full Text] [Related]
9. A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia.
Gu Y; Zhang J; Guo L; Cui S; Li X; Ding D; Kim JM; Ho SH; Hahn W; Kim S
J Gene Med; 2011 Nov; 13(11):602-10. PubMed ID: 22015632
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia.
Gu Y; Cui S; Wang Q; Liu C; Jin B; Guo W; Liu C; Chu T; Shu C; Zhang F; Han C; Liu Y
Mol Ther; 2019 Dec; 27(12):2158-2165. PubMed ID: 31805256
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Critical Limb Ischemia by pIRES/VEGF165/HGF Administration.
Barć P; Antkiewicz M; Śliwa B; Baczyńska D; Witkiewicz W; Skóra JP
Ann Vasc Surg; 2019 Oct; 60():346-354. PubMed ID: 31200059
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease.
Taniyama Y; Morishita R; Aoki M; Nakagami H; Yamamoto K; Yamazaki K; Matsumoto K; Nakamura T; Kaneda Y; Ogihara T
Gene Ther; 2001 Feb; 8(3):181-9. PubMed ID: 11313789
[TBL] [Abstract][Full Text] [Related]
13. Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study.
Henry TD; Hirsch AT; Goldman J; Wang YL; Lips DL; McMillan WD; Duval S; Biggs TA; Keo HH
Gene Ther; 2011 Aug; 18(8):788-94. PubMed ID: 21430785
[TBL] [Abstract][Full Text] [Related]
14. Beperminogene perplasmid for the treatment of critical limb ischemia.
Suda H; Murakami A; Kaga T; Tomioka H; Morishita R
Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1145-56. PubMed ID: 25190335
[TBL] [Abstract][Full Text] [Related]
15. Impairment of collateral formation in lipoprotein(a) transgenic mice: therapeutic angiogenesis induced by human hepatocyte growth factor gene.
Morishita R; Sakaki M; Yamamoto K; Iguchi S; Aoki M; Yamasaki K; Matsumoto K; Nakamura T; Lawn R; Ogihara T; Kaneda Y
Circulation; 2002 Mar; 105(12):1491-6. PubMed ID: 11914260
[TBL] [Abstract][Full Text] [Related]
16. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results.
Isner JM; Baumgartner I; Rauh G; Schainfeld R; Blair R; Manor O; Razvi S; Symes JF
J Vasc Surg; 1998 Dec; 28(6):964-73; discussion 73-5. PubMed ID: 9845647
[TBL] [Abstract][Full Text] [Related]
17. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.
Powell RJ; Simons M; Mendelsohn FO; Daniel G; Henry TD; Koga M; Morishita R; Annex BH
Circulation; 2008 Jul; 118(1):58-65. PubMed ID: 18559703
[TBL] [Abstract][Full Text] [Related]
18. No influence of tumor growth by intramuscular injection of hepatocyte growth factor plasmid DNA: safety evaluation of therapeutic angiogenesis gene therapy in mice.
Matsuki A; Yamamoto S; Nakagami H; Aoki M; Tamai K; Matsumoto K; Nakamura T; Ogihara T; Kaneda Y; Morishita R
Biochem Biophys Res Commun; 2004 Feb; 315(1):59-65. PubMed ID: 15013425
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia.
Shigematsu H; Yasuda K; Iwai T; Sasajima T; Ishimaru S; Ohashi Y; Yamaguchi T; Ogihara T; Morishita R
Gene Ther; 2010 Sep; 17(9):1152-61. PubMed ID: 20393508
[TBL] [Abstract][Full Text] [Related]
20. Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy.
Ajroud-Driss S; Christiansen M; Allen JA; Kessler JA
Mol Ther; 2013 Jun; 21(6):1279-86. PubMed ID: 23609019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
